Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Revenue of Rain Therapeutics Inc. (RAIN)
Revenue in 2022 (TTM): $
According to Rain Therapeutics Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Rain Therapeutics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $ | $-77,136,000 | $-75,721,000 | $-75,724,000 |
| 2021 | $ | $ | $-51,392,000 | $-51,392,000 | $-51,394,000 |
| 2020 | $ | $ | $-20,896,000 | $-21,083,000 | $-19,196,000 |
| 2019 | $ | $ | $-10,842,000 | $-10,902,000 | $-10,683,000 |